Can You Stop Lupron and Switch to Radiation After MRI in Prostate Cancer?
No, you should not stop Lupron (leuprolide) after MRI and switch to radiation alone—instead, continue the Lupron through radiation and for a defined period afterward based on your risk category. The MRI is a staging tool, not a decision point for discontinuing androgen deprivation therapy (ADT).
The Evidence-Based Approach
For High-Risk Disease
Neoadjuvant and concurrent ADT for 4-6 months are recommended, followed by adjuvant ADT for 2-3 years total when receiving radiation therapy 1. This means:
- Start Lupron 2-4 months before radiation begins
- Continue Lupron during radiation treatment
- Continue Lupron for 2-3 years total after starting radiation
The TROG 96-01 trial demonstrated that 6 months of hormone therapy with radiation significantly improved overall mortality (HR 0.63) compared to radiation alone 1. The EORTC 22961 trial showed that extending ADT from 6 months to 36 months in locally advanced disease reduced 5-year mortality from 19.0% to 15.2% 1.
For Intermediate-Risk Disease
Neoadjuvant and concurrent ADT for 4-6 months should be considered 1, 2. The RTOG 8610 trial showed that adding 4 months of neoadjuvant and concurrent ADT to radiation improved 10-year prostate cancer-specific mortality (23% vs 36%, P=0.01) 1.
For Low-Risk Disease
Do not use ADT at all—radiation alone or active surveillance are appropriate options 1, 2.
Why the MRI Doesn't Change This Plan
The MRI helps with:
- Staging to determine risk category (low, intermediate, or high-risk)
- Treatment planning for radiation field design
- Detecting metastases that would change the overall treatment approach
The MRI does not determine whether to stop Lupron. Once you've started ADT for intermediate or high-risk disease, the treatment protocol requires continuation through and beyond radiation based on multiple randomized controlled trials showing survival benefits 1.
Common Pitfalls to Avoid
Stopping ADT prematurely: The survival benefit comes from the full duration of treatment, not just the neoadjuvant phase. The RTOG 92-02 trial showed that extending ADT improved overall survival specifically in Gleason 8-10 patients (81.0% vs 70.7%, P=0.044) 1.
Misunderstanding the MRI's role: The MRI is for staging and planning, not for deciding when to stop systemic therapy.
Confusing neoadjuvant with total duration: "Neoadjuvant" means starting before radiation, but ADT continues concurrently during radiation and adjuvantly afterward for the full prescribed duration.
The Treatment Timeline
High-Risk Disease:
- Month 0-2: Start Lupron (neoadjuvant phase)
- Month 2-4: Continue Lupron, begin radiation
- Month 4-24 to 36: Continue Lupron (adjuvant phase)
Intermediate-Risk Disease:
- Month 0-2: Start Lupron (neoadjuvant phase)
- Month 2-4: Continue Lupron, begin radiation
- Month 4-6: Continue Lupron (total 4-6 months)
The evidence consistently shows that radiation plus ADT is superior to either modality alone for intermediate and high-risk disease 1, 2. The SPCG-7 trial demonstrated that adding radiation to ADT improved 7-year survival from 66% to 74% (P=0.003) 1.